Vistagen Therapeutics, Inc.(VTGN)— Stock Profile, AI Score & Financials

Healthcare · Nasdaq · AI-powered stock analysis, 32-signal quality score, SEC EDGAR financials, and institutional holdings. Updated 2026-06-30.

Vistagen Therapeutics, Inc. (VTGN) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. 13F Pro's AI-powered ranking engine scores VTGN at 21.9/100 on a 32-signal composite quality model, placing it at rank #2,755 of 2,962 stocks — the bottom half of the AI-ranked universe. Based on the latest XBRL financial filings (Q2 2026), Vistagen Therapeutics, Inc. reports quarterly revenue of $1.5M, net income of $-13.0M. Top institutional holders of VTGN by reported 13-F value include Commodore Capital, VANGUARD CAPITAL MANAGEMENT, TWO SIGMA INVESTMENTS, based on the most recent SEC filings. VTGN trades on the Nasdaq exchange and files with the SEC under CIK 1411685. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate VTGN daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Vistagen Therapeutics, Inc. directly from SEC EDGAR.